Do you give 3 or 4 cycles of HiDAC during consolidation for good/intermediate-risk AML without an available allotransplant donor?  

This is a complicated question because risk stratification of AML has rapidly transitioned from including clinical presenting features (age, WBC, co-morbid diseases) with cytogenetics/select mutations to now multiple mutations and other biologic features.  An example is core binding factor...